Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Unveils Next-Generation Percepta Genomic Sequencing Classifier for Improved Lung Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 20, 2019-- Veracyte, Inc . (Nasdaq: VCYT), a leading genomic diagnostics company, today announced new data demonstrating that its next-generation Percepta ® Genomic Sequencing Classifier (GSC) provides expanded lung cancer risk information that can
View HTML
Toggle Summary Veracyte Names Sangeeta Bhorade, M.D., Medical Director of Pulmonology
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has named Sangeeta Bhorade , M.D., medical director of pulmonology. In this role, Dr. Bhorade will lead medical affairs for Veracyte’s
View HTML
Toggle Summary Veracyte to Present at the UBS Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 9, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at the UBS Global Healthcare Conference in New York City on 
View HTML
Toggle Summary Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 7, 2019-- Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 6,325,000 shares of common stock, including 825,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price
View HTML
Toggle Summary Veracyte Announces Pricing of Public Offering of 5,500,000 Shares of Common Stock
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 2, 2019-- Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $23.25 per share.
View HTML
Toggle Summary Veracyte Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 1, 2019-- Veracyte, Inc. (Nasdaq: VCYT) (“the Company”) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares are being offered by Veracyte .
View HTML
Toggle Summary Veracyte Announces First Quarter 2019 Financial Results
Grew Revenue by 47% to $29.5 Million Grew Genomic Test Volume by 33% to 9,162 Tests Company Raises 2019 Annual Revenue Guidance Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 30, 2019-- Veracyte, Inc.
View HTML
Toggle Summary Veracyte Receives Regulatory Authorization to Offer Envisia Genomic Classifier for Patients in New York State
Novel Genomic Test Helps Improve Diagnosis of Idiopathic Pulmonary Fibrosis SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 22, 2019-- Veracyte, Inc . (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that it has received regulatory authorization from the New York State
View HTML
Toggle Summary Veracyte Names Alfred Bowie, Jr., Ph.D. as Vice President, Corporate and Business Development
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 22, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has named Alfred “Freddie” Bowie, Jr., Ph.D., as vice president, corporate and business development. In this role, Dr.
View HTML
Toggle Summary Veracyte Announces Publication Highlighting Afirma GSC’s Ability to Rule Out Cancer in Challenging Thyroid Nodule Subtype
RNA whole-transcriptome and machine learning platform enables genomic test to distinguish benign Hürthle cells, reducing potential for unnecessary surgeries SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 8, 2019-- Veracyte, Inc . announced today that a new study published online in BMC Systems
View HTML